AtriCure, Inc. ATRC 深 滬
已收盤 02-06 16:00:00 美东时间
37.11
+0.910
+2.51%
華盛通- 最 高37.6776
- 今 開36.71
- 成交量 39.85万股
- 最 低 36.22
- 昨 收 36.20
- 總市值 18.45亿
- 52周最高 43.18
- 市盈率 靜 --
- 換手率 0.80%
- 52周最低 28.29
- 委 比 -52.15%
- 總股本 4971.70万
- 歷史最高 89.18
- 量 比 0.77
- 振 幅 4.03%
- 歷史最低 5.90
- 每 手 1
- 風險率 3.22%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多AtriCure shares are trading lower. The company announced preliminary Q4, FY25 financial results and issued FY26 financial guidance.
AtriCure shares are trading lower. The company announced preliminary Q4, FY25 f...
01-13 04:02
AtriCure Reports Preliminary Q4 2025 Revenue Of $140.5M; FY25 Revenue Of $534.5M; Projects Positive Adjusted EBITDA Of $57M-$59M, Adjusted Loss Per Share $(0.18) To $(0.21)
AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced
01-12 23:23
Alphatec is the top performing healthcare equipment stock YTD
The S&P healthcare index (XLV) saw moderate gains in 2025, reaching a YTD increase of 12.2% by mid-December, though it fell short of its May highs. The sector is the sixth-highest performing sector a...
2025-12-23 01:12
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
JP Morgan Maintains Overweight on AtriCure, Raises Price Target to $48
JP Morgan analyst Lilia-Celine Lozada maintains AtriCure (NASDAQ:ATRC) with a Overweight and raises the price target from $42 to $48.
2025-12-16 23:36
美股大行评级 | 最高350美元！16家大行上调谷歌目标价！Meta遭12家大行下调目标价；潜在涨幅1456.29%！NRX Pharmaceuticals获Ascendiant Capital升目标价至47美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从46美元升至47美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从27美元升至31美元
2025-10-31 10:25
Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $64
Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $53 to $64.
2025-10-30 21:27
AtriCure Enrolls, Treats First Patient In BoxX-NoAF Clinical Study In Orlando, Florida
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that the
2025-10-28 20:08
AtriCure shares are trading higher after the company reported better-than-expected Q2 sales results and raised its FY25 guidance above estimates.
AtriCure shares are trading higher after the company reported better-than-expec...
2025-07-30 04:19
AtriCure Q2 Adj. EPS $(0.02) Beats $(0.17) Estimate, Sales $136.139M Beat $130.171M Estimate
AtriCure (NASDAQ:ATRC) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.17) by 88.1 percent. This is a 88.24 percent increase over losses of $(0.17) per share from the same
2025-07-30 04:04
